1Rdizzone S,PorroG B.Comparative tolerability of therapies for ulcerative colitis.Drug Saf,2002,25:561
2Hirohat S,Ohshima N,Yanagida T,et al.Regulation of human B cell function by sulfasalazine and its metabolites.Int Immunopharmacol,2002,2(5):631
3Gisbert JP,Gomollon F,Mate J,et al.Role of 5-aminosalicylicacid(5ASA)in treatment of inflammatory bowel diseasea systematic review.Dig Dis Sci,2002,47(3):471
4Frandsen NE,Saugmann S,Marcussen N.Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.Nephron,2002,92(1):200
5Malchow HA.A new mesalazine foam enema compared with a standard liquid enema in patients with active distal ulcerative colitis.Aliment Pharmacol Ther,2002,16(3):415
6Knoll U,Strauhs P.Study of the plasma pharmacokinetics and faecal excretion of the prodrug olsalazine and its metabolites after oral administration to horses.Vet Pharmacol Ther,2002,25:135
7Schmidt C,Math BM.Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease.Path-biology,2002,70(3):177
8Musch E,Andus T.Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis.Alimentary Pharmacology and Therapeutics,2002,16:1233
9Madsen SM,Schlichting P,Davidsen B,et al.An open-labeled,randomized study comparing systemic interferon-alpha-2A and prednisone enemas in the treatment of left-sided ulcerative colitis.The American Journal of Gastroenterology,2001,96(6):1807
10Middleton SJ,Naylor S,Wooler J,et al.A double-blind,randomized placebo-controlled trial of essential fatty acid supplemention in the maintance of ulcerative colitis.Alimentary Pharmacology and Therapeutics,2002,16(6):1131
二级参考文献20
1Sinha VR, Kumria R. Microbially triggered drug delivery to the colon[J]. Eur J Pharm Sci, 2003, 18(1):3-18.
2Khan MZ, Stedul HP, Kurjakovic N. A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. Ⅱ. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations[J]. Drug Det, Ind Pharm, 2000, 26(5):549-554.
3Sangalli ME, Maroni A, Zema L, et al. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivety[J]. J Control Rdease, 2001, 73( 1): 103 -110
4Muraoka M, Hu Z, Shimokawa T, et al. Evaluation of intestinal pressure-controlled colon deliveny capsule containing caffeine as a model drug in human volunteers[J].J Control, 1998, 52(1/2):119- 129.
5Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation[ J ]. Int J Pharm, 2002, 235(1/2) : 1 - 15.
6Prasad YV, Krishnaiah YS, Satyanarayana S. In vitro evaluation of guar gum as a cartier for colon-specific drug delivery[J]. J Control Release, 1998, 51(2/3):281-287.
7Wiwattanapatapee R,Lomlim L,Saramunee K.Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid[J].J Control Release,2003,88(1):1-9
8Cai Q,Zhu K, Chen D, et al. Synthesis, characterizalion and in vitro release of 5-aminosalicylic acid and 5-acetyl aminosalicylic acid of polyanhydride - P(CBFAS) [J]. Eur J Pharm Biopharm, 2003, 55(2):203-208.
9Krishnaiah YS, Karthikeyan RS, Gouri Sankar V, et al.Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine dihydrochloride[J].J Control Release, 2002, 81(1/2) :45 -56.
10Hirsch L, Binder V, Scheblmann V, et al.Lauroyldextran and crosslinked galactomannan as coating materials for sitespecific drug delivery to the colon[J]. Fur J Pharm Biolpharm, 1999, 47(1):61-71.
7Sandor Z,Deng XM,Khomenko T, et al. Altered angiogenic balance in ulcerative colitis: a key to impaired healing? [J]. Biochem Biophys Res Commun,2006,350(1):147 150.
8Sclano G.Asthma,nasal polyposis and ulcerative colitis: a new perspective[J]. Clin Exp Allergy,2002,32 (8) :1144-1149.
9Deng X,Szabo S,Khomenko T, et al. Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats[J]. J Pharmacol Exp Ther,2004,311(3):982 988.
10Tombran-Tink J,Lara N,Apricio SE,et al. Retinoic acid and dexamethasone regulate the expression of PEDF in retinal and endothelial cells[J]. Exp Eye Res,2004,78(1):945 55.
